



In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 8.01 Other Events.

On December 9, 2013, Array BioPharma issued two press releases. The press releases announced that Array provided clinical updates on two drug candidates, newly named filanesib (ARRY-520), a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, both of which were presented at the 2013 Annual Meeting of the American Society of Hematology (ASH).

Copies of the press releases are attached to this Form 8-K as Exhibit 99.1 and Exhibit 99.2 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release announcing clinical update on filanesib (ARRY-520) for multiple myeloma at the 2013 ASH Meeting
99.2	Press Release announcing clinical update on ARRY-614 for myelodysplastic syndromes at the 2013 ASH Meeting

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 9, 2013

Array BioPharma Inc.

By: /s/ R. Michael Carruthers
R. Michael Carruthers
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release announcing clinical update on filanesib (ARRY-520) for multiple myeloma at the 2013 ASH Meeting
99.2	Press Release announcing clinical update on ARRY-614 for myelodysplastic syndromes at the 2013 ASH Meeting